Get access

Comparative Cardiovascular Safety of Dementia Medications: A Cross-National Study

Authors

  • Emil L. Fosbøl MD, PhD,

    Corresponding author
    1. Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
    • Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author
  • Eric D. Peterson MD, MPH,

    1. Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    2. Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author
  • Ellen Holm MD,

    1. Department of Geriatrics, Roskilde University Hospital, Roskilde, Denmark
    Search for more papers by this author
  • Gunnar H. Gislason MD, PhD,

    1. Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
    Search for more papers by this author
  • Yinghong Zhang BA,

    1. Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author
  • Lesley H. Curtis PhD,

    1. Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    2. Department of Geriatrics, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author
  • Lars Køber MD, DMSc,

    1. Department of Cardiology, Heart Center, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
    Search for more papers by this author
  • Isao Iwata MD, PhD,

    1. Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    2. Department of Geriatrics, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author
  • Christian Torp-Pedersen MD, DMSc,

    1. Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark
    Search for more papers by this author
  • Soko Setoguchi MD, DrPH

    1. Duke Clinical Research Institute, School of Medicine, Duke University, Durham, North Carolina
    2. Department of Medicine, School of Medicine, Duke University, Durham, North Carolina
    Search for more papers by this author

Address correspondence to Emil L. Fosbøl, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27705. E-mail: emil.fosbol@duke.edu

Abstract

Objectives

To compare the cardiovascular safety of currently marketed dementia medications in new users in the United States and Denmark.

Design

Retrospective cohort study.

Setting

Nationally representative sample of Medicare beneficiaries from 2006 through 2009 and nationwide Danish administrative registries from 1997 through 2007.

Participants

Individuals treated with a dementia medication aged 65 and older.

Measurements

Hospitalizations for myocardial infarction (MI), heart failure, and syncope or atrioventricular block in both cohorts; fatal or nonfatal MI and cardiac death in the Danish cohort; and all-cause mortality in sensitivity analyses.

Results

In 46,737 Medicare beneficiaries and 29,496 Danish participants, donepezil was the most frequently used medication. There were no substantial differences in the risk of MI or heart failure between participants using donepezil and those using other cholinesterase inhibitors (all hazard ratios (HR) crossing 1). In the Danish cohort, memantine was associated with fatal or nonfatal MI (HR = 1.33, 95% confidence interval (CI) = 1.08–1.63), cardiac death (HR = 1.31, 95% CI = 1.12–1.53), and a trend toward higher rates of hospitalization for MI (HR = 1.31, 95% CI = 0.98–1.76). Memantine was also associated with greater risk of all-cause mortality in the Medicare (HR = 1.20, 95% CI = 1.13–1.28) and Danish (HR = 1.83, 95% CI = 1.73–1.94) cohorts, suggesting that sicker individuals were selected for memantine therapy.

Conclusion

Cholinesterase inhibitors have similar cardiovascular risk profiles. Associations between memantine and fatal outcomes in Denmark may be related, in part, to selection of sicker individuals for memantine therapy.

Get access to the full text of this article

Ancillary